PMID- 16899613
OWN - NLM
STAT- MEDLINE
DCOM- 20071214
LR  - 20060810
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 12
IP  - 15
DP  - 2006 Aug 1
TI  - Effect of human leukocyte antigen class I expression of tumor cells on outcome of 
      intravesical instillation of bacillus calmette-guerin immunotherapy for bladder 
      cancer.
PG  - 4641-4
AB  - PURPOSE: Various immune systems play important roles in the clinical efficacy of 
      intravesical Bacillus Calmette-Guerin (BCG) instillation for bladder cancer. 
      However, human leukocyte antigen (HLA) class I molecules on tumor cells and 
      various immune system cells infiltrating to/around the tumor have not been 
      evaluated, although many prognostic factors, including clinical, pathologic, and 
      molecular ones, have been investigated. The aim of this study was to determine 
      immunologic prognostic factors of BCG immunotherapy for bladder cancer. 
      EXPERIMENTAL DESIGN: Immunohistochemical staining for HLA class I, CD4, CD8, 
      CD20, CD68, TIA-1, S-100, and FOXP3 was carried out on specimens from 30 patients 
      who underwent BCG immunotherapy from whom both pretreatment and posttreatment 
      specimens were obtained. We did univariate and multivariate analyses of factors 
      affecting recurrence-free survival. The positive, weakly positive, and negative 
      groups of cells that infiltrated to/around the tumor were compared with 
      recurrence-free survival using the Kaplan-Meier method and log-rank test. 
      RESULTS: HLA class I was a significant prognostic factor both in univariate and 
      multivariate analyses. The 5-year recurrence-free survivals of the patients with 
      HLA class I-positive tumors and those with HLA class I-negative tumors were 55.7% 
      and 19.1%, respectively (P = 0.019). There was a significant association between 
      infiltration of CD8, CD20, and CD68-positive cells after BCG therapy and 
      therapeutic effects. CONCLUSIONS: Our data show that expression of HLA class I 
      molecules on tumor cells contributes significantly to the therapeutic effect of 
      BCG immunotherapy for bladder cancer. It is suggested that CTLs may be one of 
      main effectors in this therapy.
FAU - Kitamura, Hiroshi
AU  - Kitamura H
AD  - Department of Urology, Sapporo Medical University School of Medicine, Sapporo, 
      Japan. hkitamu@sapmed.ac.jp
FAU - Torigoe, Toshihiko
AU  - Torigoe T
FAU - Honma, Ichiya
AU  - Honma I
FAU - Sato, Eiji
AU  - Sato E
FAU - Asanuma, Hiroko
AU  - Asanuma H
FAU - Hirohashi, Yoshihiko
AU  - Hirohashi Y
FAU - Sato, Noriyuki
AU  - Sato N
FAU - Tsukamoto, Taiji
AU  - Tsukamoto T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (BCG Vaccine)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Adjuvants, Immunologic/*administration & dosage
MH  - Administration, Intravesical
MH  - BCG Vaccine/*administration & dosage/immunology
MH  - Disease-Free Survival
MH  - Follow-Up Studies
MH  - Histocompatibility Antigens Class I/*biosynthesis
MH  - Humans
MH  - Immunohistochemistry
MH  - Immunotherapy
MH  - Predictive Value of Tests
MH  - Treatment Outcome
MH  - Urinary Bladder Neoplasms/diagnosis/*immunology/*therapy
EDAT- 2006/08/11 09:00
MHDA- 2007/12/15 09:00
CRDT- 2006/08/11 09:00
PHST- 2006/08/11 09:00 [pubmed]
PHST- 2007/12/15 09:00 [medline]
PHST- 2006/08/11 09:00 [entrez]
AID - 12/15/4641 [pii]
AID - 10.1158/1078-0432.CCR-06-0595 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2006 Aug 1;12(15):4641-4. doi: 10.1158/1078-0432.CCR-06-0595.